20/20 Biolabs, Inc. (AIDX) Income Statement
AIDX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAIDX revenue and net income
Where AIDX's revenue goes
2025Each bar shows an amount and its share of revenue. AIDX kept −182.8% of revenue as net income.
AIDX profit margins
AIDX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +16.7% | −43.0% | −2.6% | — |
| Gross profit | +67.8% | −50.9% | −7.2% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AIDX quarterly EPS vs estimates
20/20 Biolabs beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 13, 2026.
AIDX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.8M | $1.4M | $11.1M | $9.6M | $2.3M | $288,300 | $277,047 | $313,207 | $427,000 |
| Cost of revenue | $1.4M | $1.4M | $1.3M | $5.9M | $4.9M | $1.5M | $263,917 | $217,595 | $182,275 | $256,220 |
| Gross profit | $604,541 | $360,311 | $109,138 | $5.1M | $4.7M | $877,174 | $24,383 | $59,452 | $130,932 | $170,780 |
| Research & development | $592,569 | $1.3M | $1.4M | $120,043 | $193,368 | $338,874 | $195,041 | $234,492 | $267,063 | $424,426 |
| Sales, general & admin | $3.3M | $4.8M | $5.1M | — | — | — | — | — | — | — |
| Total operating expenses | $3.9M | $6.0M | $6.5M | $3.4M | $2.8M | $2.9M | $2.5M | $1.5M | $1.4M | $2.4M |
| Operating income | −$3.3M | −$5.7M | −$6.4M | $1.7M | $1.9M | −$2.0M | −$2.5M | −$1.5M | −$1.3M | −$2.2M |
| Interest income | $21,399 | $79,467 | $209,150 | — | — | — | — | — | — | — |
| Interest expense | $156,207 | $12,646 | $27,915 | $15,685 | $12,930 | — | — | — | — | $9,472 |
| Income before taxes | −$3.7M | −$5.6M | −$6.4M | $2.2M | $2.1M | −$2.0M | −$2.4M | −$1.5M | −$1.3M | −$2.2M |
| Net income | −$3.7M | −$5.6M | −$6.4M | $2.2M | $2.1M | −$2.0M | −$2.4M | −$1.5M | −$1.3M | −$2.2M |
| EBITDA | −$3.5M | −$5.5M | −$6.2M | $2.0M | $2.1M | −$2.0M | −$2.4M | −$1.4M | −$1.3M | −$2.2M |
| EPS (diluted) | −$0.13 | −$1.15 | −$1.34 | — | — | — | — | — | — | — |
| Gross margin | 29.6% | 20.6% | 7.7% | 46.3% | 48.8% | 37.6% | 8.5% | 21.5% | 41.8% | 40.0% |
| Operating margin | −162.9% | −323.1% | −446.6% | 15.2% | 20.2% | −87.1% | −855.8% | −532.1% | −408.4% | −522.4% |
| Net margin | −182.8% | −316.8% | −448.7% | 19.8% | 21.5% | −86.8% | −841.3% | −528.1% | −403.6% | −521.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $730,571 | $353,375 | $538,274 | $417,979 | $535,060 | $553,820 | $536,084 | $361,009 | $335,936 | $419,381 |
| Cost of revenue | $425,844 | $290,491 | $407,857 | $272,913 | $371,796 | $388,025 | $373,054 | $336,869 | $296,817 | $417,521 |
| Gross profit | $304,727 | $62,884 | $130,417 | $145,066 | $163,264 | $165,795 | $163,030 | $24,140 | $39,119 | $1,859 |
| Research & development | $257,632 | $153,482 | $130,554 | $131,060 | $194,124 | $136,831 | $446,056 | $297,099 | $513,722 | $115,525 |
| Sales, general & admin | $1.3M | $1.4M | $912,709 | $814,179 | $814,811 | $801,144 | $960,972 | — | — | — |
| Total operating expenses | $1.5M | $1.5M | $1.0M | $945,239 | $1.4M | $1.3M | $1.4M | $1.9M | $1.8M | $1.8M |
| Operating income | −$1.2M | −$1.4M | −$912,846 | −$800,173 | −$845,671 | −$772,180 | −$1.2M | −$1.9M | −$1.8M | −$1.8M |
| Interest income | $14,476 | $6,653 | $3,087 | $4,181 | $5,673 | $8,458 | $11,270 | — | — | — |
| Interest expense | $272,245 | $267,008 | $124,985 | $29,547 | $935 | $740 | $0 | — | $7,096 | $7,147 |
| Income before taxes | −$1.5M | −$2.2M | −$1.3M | −$825,539 | −$840,933 | −$764,577 | −$1.2M | −$1.9M | −$1.7M | −$2.0M |
| Net income | −$1.5M | −$2.2M | −$1.3M | −$825,539 | −$840,933 | −$764,577 | −$1.2M | −$1.9M | −$1.7M | −$2.0M |
| EBITDA | −$1.2M | −$1.9M | −$894,972 | −$780,949 | −$820,732 | — | −$1.2M | −$1.9M | −$1.7M | −$1.8M |
| EPS (diluted) | −$0.26 | −$0.28 | −$0.13 | — | — | — | — | — | — | — |
| Gross margin | 41.7% | 17.8% | 24.2% | 34.7% | 30.5% | 29.9% | 30.4% | 6.7% | 11.6% | 0.4% |
| Operating margin | −170.3% | −408.4% | −169.6% | −191.4% | −158.1% | −139.4% | −232.1% | −523.7% | −526.0% | −437.6% |
| Net margin | −206.2% | −615.4% | −243.0% | −197.5% | −157.2% | −138.1% | −233.0% | −519.0% | −511.0% | −475.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AIDX's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AIDX financial results
In fiscal year 2025 (ended December 31, 2025), 20/20 Biolabs reported revenue of $2.0 million, up 16.7% from the year before. It had a net loss of $3.7 million, a net profit margin of −182.8%. Diluted earnings per share came to −$0.13. Over five years revenue grew at an average rate of −2.6% a year.
See the AIDX stock overview for the latest quote and news, or the AIDX chart for price history and technical indicators.
AIDX income statement FAQ
What is 20/20 Biolabs's annual revenue?
20/20 Biolabs reported total revenue of $2.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 16.7% from $1.8 million the previous year.
Is 20/20 Biolabs profitable?
No. 20/20 Biolabs reported a net loss of $3.7 million in fiscal 2025, a net profit margin of −182.8%; its operating margin was −162.9%.
What is 20/20 Biolabs's gross margin?
20/20 Biolabs's gross margin was 29.6% in fiscal 2025: for every $100 of revenue, 20/20 Biolabs kept $30 after the direct cost of its products and services.
How much does 20/20 Biolabs spend on research and development?
20/20 Biolabs spent $0.6 million on research and development in fiscal 2025, 29.0% of revenue.
How fast is 20/20 Biolabs growing?
Revenue grew −2.6% a year on average over the last five fiscal years, from $2.3 million to $2.0 million.
What are 20/20 Biolabs's earnings per share?
20/20 Biolabs earned $-0.13 per diluted share in fiscal 2025, compared with $-1.15 a year earlier.
When will 20/20 Biolabs report its next earnings?
20/20 Biolabs is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does 20/20 Biolabs's fiscal year end?
20/20 Biolabs's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.